LNA043 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
LNA043 is an innovative ANGPTL3 agonist designed to specifically target and repair damaged cartilage. Read more about LNA043 Osteoarthritis pipeline report
SPRIFERMIN OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
Sprifermin (AS-902330) is a recombinant version of human fibroblast growth factor 18 (FGF18). Get more insights into Sprifermin Osteoarthritis pipeline report
TLC599 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
TLC599 is a proprietary formulation of dexamethasone sodium phosphate (DSP) utilizing the BioSeizer technology. Read more about TLC599 Osteoarthritis report
WEGOVY OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
WEGOVY (Semaglutide) is a synthetic version of the human glucagon-like peptide-1 (GLP-1) hormone. Get more insights into WEGOVY Osteoarthritis pipeline report
X0002 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
X0002, also known as ibuprofenamine hydrochloride spray, is an innovative transdermal non-steroidal anti-inflammatory drug. Read more about X0002 Osteoarthritis